Skip to main content
SpringerLink
Log in

A rational approach to short stature: Focus on use and abuse of growth hormone

  • Symposium: Endocrinology—Part II
  • Published:
The Indian Journal of Pediatrics Aims and scope Submit manuscript

Abstract

The abundant supply of recombinant growth hormone has raised interesting possibilities of several new applications. While supplementation of the missing hormone in patients with growth hormone deficiency is still the undisputed primary indication for its use, there is now convincing evidence of its usefulness in the therapy of short stature due to Turner syndrome and pre-transplant chronic renal failure in childhood. Numerous studies on patients with other causes of short stature have failed to show any significant benefit in final adult height. Social pressures notwithstanding, it is still premature to advocate the use of this expensive therapy for indications other than the three stated above especially since our understanding of potential long-term complications from such treatment is far from complete.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Spiliotis BE, August GP, Hung W, Senis W, Mendelson W, Bercu BB. Growth hormone neurosecretory dysfunction: A treatable cause for short stature.JAMA 1984; 251: 2223–2230.

    Article  PubMed  CAS  Google Scholar 

  2. Zadik Z, Chalew S, Zung A,et al. Effect of long-term growth hormone therapy on bone age and pubertal maturation in boys with and without classic growth hormone deficiency.J. Pediatr 1994; 125: 198–195.

    Google Scholar 

  3. Guidelines for the use of growth hormone in children with short stature. A report by the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society.J. Pediatr 1995; 127: 857–867.

  4. Celniker AC, Chen AB, Wert RM, Sherman BM. Variability in the quantitation of ciruclating growth hormone using commerical immunoassays.J. Clin Endocrinol Metab 1989; 68: 469–476.

    Article  PubMed  CAS  Google Scholar 

  5. Allen DB, Brook CGD, Bridges NA, Hindmarsh PC, Guyda HJ, Frazier D. Therapeutic controversies: Growth hormone (GH) treatment of non-GH deficient subjects.J Clin Endocrinol Metab 1994; 79: 1239–1248.

    Article  PubMed  CAS  Google Scholar 

  6. Price DA, Johnston DI, Betts PR, Buckler JMH, Donaldson MDC. Biosynthetic human growth hormone treatment in the UK: An audit of current practice.Arch Dis Child 1994; 71: 266–271.

    PubMed  CAS  Google Scholar 

  7. Darendeliler F, Hindmarsh PC, Brook CGD. Dose response curves for treatment with biosynthetic GH.J. Endocrinol 1990; 125: 311–316.

    PubMed  CAS  Google Scholar 

  8. Ranke MB, Guilbaud O, Lindberg A, Cole T. Prediction of the growth response in children with various growth disorders treated with growth hormone: Analysis of data from the Kabi Pharmacia International Growth Study.Acta Pediatr (Suppl) 1993; 391: 82–88.

    Article  Google Scholar 

  9. Ross JL, Long LM, Lorianz DI, Cutler Jr. GH. Growth hormone secretory dynamics in Turner syndrome.J. Pediatr 1985; 106: 202–206.

    Article  PubMed  CAS  Google Scholar 

  10. Rosenfeld RG, Frane J, Attie KM. Six-yearold results of a randomized prospective trial of human growth hormone and oxandrolone in Turner syndrome.J. Pediatr 1992; 121: 49–55.

    Article  PubMed  CAS  Google Scholar 

  11. Blum WF, Ranke MB, Kietzmann K, Tonshoff B, Mehls O, Growth hormone resistance and the inhibition of somatomedin activity by excess of Insulin-like growth factor binding protein in uremia.Pediatr Nephrol 1991; 5: 539–544.

    Article  PubMed  CAS  Google Scholar 

  12. Loche S, Cambiaso P, Setzu S,et al. Final height after growth hormone therapy in non-growth-hormone deficient children with short stature.J. Pediatr 1994; 125: 196–200.

    Article  PubMed  CAS  Google Scholar 

  13. Hopwood NJ, Hintz RL, Gertner JM,et al. Growth response of children with non-growth-hormone deficiency and marked short stature during three years of growth hormone therapy.J. Pediatr 1993; 123: 215–222.

    Article  PubMed  CAS  Google Scholar 

  14. Spagnoli A, Spadoni GL, Cianfarani S, Pasquino AM, Troiani S, Boscherini B. Prediction of the outcome of growth hormone therapy in children with idiopathic short stature.J. Pediatr 1995; 126: 905–909.

    Article  PubMed  CAS  Google Scholar 

  15. Guyda H. Final height attainment in normal children with short stature treated with growth hormone. International Task Force (ITF) Report.Pediart Res. 1993; 33: S10 (Abstract 43).

    Article  Google Scholar 

  16. Kerrigan JR, Martha Jr PM, Veldhuis JD, Blizzard RM, Rogol AD. Altered growth hormone secretory dynamics in prepubertal males with constitutional delay of growth.Pediatr Res. 1993; 33: 278–283.

    Article  PubMed  CAS  Google Scholar 

  17. Saggese G, Cesaretti G, Barsanti S, Rossi A. Combination treatment with growth hormone and gonadotropin-releasing hormone analogs in short normal girls.J. Pediatr 1995; 126: 468–473.

    Article  PubMed  CAS  Google Scholar 

  18. Buyukgebiz A, Hindmarsh PC, Brook CGD. Treatment of constitutional delay of growth and puberty with oxandrolone compared with growth hormone.Arch Dis Child 1990; 65: 448–449.

    PubMed  CAS  Google Scholar 

  19. Tse W-y, Buyukgebiz A, Hindmarsh PC, Stanhope R, Preece MA, Brook CGD. Long term outcome of oxandrolone treatment in boys with consitutional delay of growth and puberty.J. Pediatr 1990; 117: 588–591.

    Article  PubMed  CAS  Google Scholar 

  20. Papadimitriou A, Wacharasindhu S, Pearl K, Preece MA, Stanhope R. Treatment of constitutional growth delay in prepubertal boys with a prolonged course of low dose oxandrolone.Arch Dis Child 1991; 66: 841–843.

    PubMed  CAS  Google Scholar 

  21. Paz I, Seidman DS, Dannon YL, Laor A, Stevenson DK, Gale R. Are children born small for gestational age at increased risk of short stature?.Am J Dis Child 1993; 147: 337–339.

    PubMed  CAS  Google Scholar 

  22. Hokken-Kolega ACA, Stijnen T, deRidder MAJet al. Growth hormone treatment in growth-retarded adolescents after renal transplant.Lancet 1994; 343: 1313–1317.

    Article  Google Scholar 

  23. Castells S, Wisniewski KE. Growth hormone treatment in Down syndrome-editorial correspondence.J. Pediatr 1994; 124: 158–159.

    Article  PubMed  CAS  Google Scholar 

  24. Nishi Y, Kajiyama M, Miyagawa S, Fujiwara M, Hamamoto K. Growth hormone therapy in Achondroplasia.Acta Endocrinol 1993; 128: 394–396.

    PubMed  CAS  Google Scholar 

  25. Lov LC, Kwan EY, Lim YJ, Lee AC, Tam CF, Lam KF. Growth hormone treatment of short Chinese children with betathalassemia major without GH deficiency.Clin Endocrinol 1995; 42: 359–363.

    Google Scholar 

  26. Davies UM, Rooney M, Preece MA, Ansell BM, Woo P. Treatment of growth retardation in juvenile chronic arthritis with recombinant human growth hormone.J Rheumatol 1994; 21: 153–158.

    PubMed  CAS  Google Scholar 

  27. Sandberg DE, Brooke AE, Campos SP. Short stature: A psychosocial burden requiring growth hormone therapy?.Pediatrics 1994; 94: 832–840.

    PubMed  CAS  Google Scholar 

  28. Pilpel D, Leiberman E, Zadik Z, Carel CA. Effect of growth hormone treatment on quality of life of short stature children.Horm Res. 1995; 44: 1–5.

    Article  PubMed  CAS  Google Scholar 

  29. Ezzat S, Strom C, Melmed S. Colon polyps in acromegaly.Ann Int Med 1991; 114: 754–755.

    PubMed  CAS  Google Scholar 

  30. Barker DJP, Osmond C, Golding J. Height and mortality in the countries of England and Wales.Ann Hum Biol 1990; 17: 1–6.

    Article  PubMed  CAS  Google Scholar 

  31. Fradkin JE, Schonberger LB, Mills JLet al. Creutzfeldt-Jakob disease in pituitary growth hormone recipients in the United States.JAMA 1991; 265: 880–884.

    Article  PubMed  CAS  Google Scholar 

  32. Buchanan CR, Preece MA, Milner RDG. Mortality, neoplasia and Creutzfeldt-Jakob disease in patients treated with human pituitary growth hormone in the United Kingdom.BMJ 1991; 302: 824–828.

    PubMed  CAS  Google Scholar 

  33. Malozowski S, Tanner LA, Wysowski DK, Flemming GA. Growth hormone, insulin-like growth factor I and benign intracranial hypertension.N Engl J Med 1993; 329: 665–666.

    Article  PubMed  CAS  Google Scholar 

  34. McCaughey ES, Mulligan J, Voss LD, Betts PR. Growth and metabolic consequences of growth hormone treatment in prepubertal short normal children.Arch Dis Child 1994; 71: 210–206.

    Google Scholar 

  35. Barton JS, Hindmarsh PC, Preece MA, Brook CGD. Blood pressure and the renin-angiotensin-aldosterone system in children receiving recombinant human growth hormone.Clin Endocrinol 1993; 38: 245–251.

    CAS  Google Scholar 

  36. Prasad V, Greig F, Bastian W, Castells S, Juan C, AvRuskin TW. Slipped capital femoral epiphysis during treatment with recombinant growth hormone for isolated, partial growth hormone deficiency.J Pediatr 1990; 116: 397–399.

    Article  PubMed  CAS  Google Scholar 

  37. Pirazzoli P, Cacciari E, Mandini Met al. Follow-up of antibodies to growth hormone in 210 growth hormone-deficient children treated with different commerical preparations.Acta Pediat 1995; 84: 1233–1236.

    Article  CAS  Google Scholar 

  38. Rekers-Mombarg LT, Rijkers GT, Masse GG, Wit JM. Immunologic studies in children with idiopathic short stature before and during growth hormone therapy. Dutch Growth Hormone Working Group.Horm Res. 1995; 44: 203–207.

    Article  PubMed  CAS  Google Scholar 

  39. Chavers BM, Doberty L, Nevins TE, Cook M, Sane K. Effects of growth hormone on kidney function in pediatric transplant recipients.Pediatr Nephrol 1995; 9: 176–181.

    Article  PubMed  CAS  Google Scholar 

  40. Vihervuori E, Siplia I, Siimes MA. Increases in hemoglobin concentration and iron needs in response to growth hormone treatment.J Pediat 1994; 125: 242–245.

    Article  PubMed  CAS  Google Scholar 

  41. Rickert VI, Pawlak-Morello C, Sheppard V, Jay MS. Human growth hormone: A new substance of abuse among adolescents.Clin Pediatr 1992; 31: 723–726.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Texas Tech University Health Sciences Center, Lubbock, Texas

    I. Krishna

Authors
  1. I. Krishna
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krishna, I. A rational approach to short stature: Focus on use and abuse of growth hormone. Indian J Pediatr 64, 145–152 (1997). https://doi.org/10.1007/BF02752434

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02752434

Key words

Search

Navigation